|Day Low/High||85.81 / 86.40|
|52 Wk Low/High||73.69 / 89.09|
Data from a Phase 2 trial will be presented for the first time at the ADA's 78th Scientific Sessions®
Markets had a tumultuous week starting with increased trade war fears and ending with a modest oil production increase from OPEC.
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc.
Pharma firm's new diabetes drug showed positive test results.
INDIANAPOLIS, June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.
While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.
Jim discusses news on Qualcomm-NXP Semiconductors, why we would sell Constellation today, and mentions Raytheon, Eli Lilly, PepsiCo, Honeywell and Emerson Electric!
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.
Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.
Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!
U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.
Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
Jim discusses a Cimarex upgrade, Eli Lilly receiving positive attention, Microsoft and gaming, Facebook, and answers a club member's question on PepsiCo!
Manufacturer gives swine producers a new tool to combat the devastating disease
Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus
INDIANAPOLIS, June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini-tender offer by TRC Capital Corp.
Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.
- New data are the first safety and efficacy data for an IL-23p19 monoclonal antibody for the treatment of moderate-to-severe ulcerative colitis -
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.